Philip Morris raises cash offer for Vectura Group

By: Miguel A. Rodriguez

10:52, 23 August 2021

The week starts with a new possible deal in the tobacco and drug-making industry

Philip Morris, the Swiss-American multinational cigarette and tobacco manufacturing company, announced that it increased its offer for Vectura Group PLC. Philip Morris is willing to spend £1.02 billion for the British pharmaceutical business.

Under the new deal, shareholders of Vectura will receive 165 pence/share in cash, up from Morris' previous offer of 150 pence a share, topping Carlyle Europe Partners V of 155 pence apiece announced Friday.

Through this deal, Philip Morris is looking to push back against critics, saying that the Vectura deal was part of a larger project meant to "build on its leading scientific capabilities to develop products and services that go Beyond Nicotine". The project was first announced in 2019.

The statement came after Vectura revealed that it had agreed to a £958 million takeover by Murano Bidco Ltd, a company indirectly controlled by funds managed by Carlyle Europe Partners V, and withdrew its recommendation for Phillip Morris' proposal.

According to Vectura, which is specialized in inhaled medicines, Carlyle offers better value to shareholders than Morris and puts the company in a better position to meet its current strategy.



Share this article

The information presented herein is prepared by and does not intend to constitute Investment Advice. The information herein is provided as a general marketing communication for information purposes only.Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience, or current financial situation. 

Key Way Markets Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance and forecasts are not reliable indicators of future results.